Brian T. Powl, Chief Commercial Officer of Kura Oncology, Inc., filed a Form 4 on November 19, 2026, disclosing the sale of 448 shares of common stock under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Reporting person: Brian T. Powl, Chief Commercial Officer of Kura Oncology, Inc.
  • Transaction: 448 shares of common stock disposed of (transaction code S) on November 19, 2026, at $7.27 per share.
  • Remaining holdings: Powl beneficially owned 112,817 shares of common stock directly following the reported transaction.
  • Trading plan: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by Powl on May 22, 2026.
  • Exchange and ticker: NASDAQ:KURA

Powl's November 2026 Share Sale Under Rule 10b5-1 Plan

According to the Form 4 filed with the SEC, Brian T. Powl, serving as Chief Commercial Officer of Kura Oncology, Inc. (NASDAQ:KURA), reported the disposition of 448 shares of the company's common stock on November 19, 2026. The shares were sold at a price of $7.27 each. The filing notes that this transaction was carried out as a direct sale, with the ownership form listed as direct.

The filing discloses that the transaction was made pursuant to a Rule 10b5-1 trading plan that Powl adopted on May 22, 2026. The checkbox on the Form 4 indicating a Rule 10b5-1(c) plan is marked, and the accompanying footnote states: "The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2026." Following the reported sale, Powl's direct beneficial ownership in Kura Oncology common stock stood at 112,817 shares, as reported in the filing.

No derivative securities transactions were reported in Table II of this filing. The Form 4 was signed by Teresa Bair as attorney-in-fact for Brian Powl, with a signature date of November 19, 2026, and was filed as an individual, single-reporting-person submission.

What Was Disclosed

Kura Oncology's Chief Commercial Officer, Brian T. Powl, disclosed the sale of 448 shares of common stock at $7.27 per share on November 19, 2026, executed under a Rule 10b5-1 plan adopted May 22, 2026, leaving him with direct beneficial ownership of 112,817 shares.